Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation <li /> Ongoing phase 2 ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

The global prostate cancer market is projected to be valued at USD 12.9 billion in 2025 and is expected to reach USD 29.2 billion by 2035, registering a CAGR of 8.5% during the forecast period, driven ...

The global weight management supplement market is gaining remarkable traction amid rising concerns over obesity, ...